Recalls
Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.
Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.
The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.
Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.
Minimum severity
AvKARE is recalling Valsartan Tablets 40 mg because a carcinogen impurity was detected in the active pharmaceutical ingredient used to manufacture the drug.
Auro Pharmacies is recalling 43 vials of Testosterone Cypionate/Enanthate injectable because inadequate processes and equipment failed to assure product sterility.
Auro Pharmacies is recalling 81 vials of Methyl-Cobalamin injectable because processes and equipment were inadequate to assure sterility.
Torrent Pharma Inc. is recalling specific batches of Amlodipine, Valsartan, and Hydrochlorothiazide tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Pharmcore Inc. is recalling 864 vials of Human Chorionic Gonadotropin 11000 IU due to a lack of assurance of sterility. The affected lots were distributed nationwide.
Auro Pharmacies is recalling 11 vials of Testosterone Enanthate/Cypionate injectable because the manufacturer could not assure the sterility of the product.
Pharmcore Inc. is recalling Ipamorelin 3 mg vials because the company cannot ensure the product is sterile.
Baxter Healthcare is recalling 33,600 bags of 0.9% Sodium Chloride Injection USP due to Current Good Manufacturing Practice (CGMP) deviations. The product was distributed only in Texas and Mississippi.
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications, potentially resulting in incorrect drug strength.
Westminster Pharmaceuticals is recalling specific lots of Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient.
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
A-S Medication Solutions LLC is recalling Valsartan and Hydrochlorothiazide Tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
A-S Medication Solutions LLC is recalling 531 bottles of Valsartan and Hydrochlorothiazide Tablets due to the detection of a carcinogen impurity in the active pharmaceutical ingredient.
Hetero Labs is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
A-S Medication Solutions LLC is recalling Valsartan Tablets 160 MG because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Preferred Pharmaceuticals is recalling Valsartan Tablets USP 320 mg because a carcinogen impurity was detected in the active pharmaceutical ingredient.
A-S Medication Solutions LLC is recalling 178 bottles of Valsartan Tablets, 80 MG, because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Ranier's Compounding Laboratory is recalling Pro/PA/PH/AT Injection in Pennsylvania due to a lack of assurance of sterility.
Ranier's Compounding Laboratory is recalling Medroxprogesterone 1% Ophthalmic Solution due to a lack of assurance of sterility. The product was distributed in Pennsylvania.
Ranier's Compounding Laboratory is recalling Acetylcysteine 10% Ophthalmic Solution due to a lack of assurance of sterility. The product was distributed in Pennsylvania.